NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
By W. Gradishar, B. Anderson, R. Balassanian, Sarah L. Blair, H. Burstein, Amy E. Cyr, A. Elias, W. Farrar, Andres Forero, S. H. Giordano and 23 more. The Journal of the National Comprehensive Cancer Network, 2017
675 citations recorded by the source corpus.
Subfields: Cancer Research, Economics and Econometrics, Oncology
View Paper: https://www.semanticscholar.org/paper/dd891b164d4b0778b0c310f5087307d21984ea1f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Breast Cancer Immunotherapy: Facts and Hopes (2017, background): “It can be classified into three major clinically relevant subtypes that are managed differently: luminal [expressing the estrogen receptor (ER) and/or progesterone receptor (PR)]; human epidermal growth factor receptor-2þ (HER-2þ); and triple-negative, lacking expression of ER, PR, and HER-2 (14).”